Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

On Tuesday, Valneva SE VALN revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.

The results align with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.

The three-year persistence data align with the twelve-month and two-year persistence data the company reported in December 2022 and 2023, respectively.

Also Read: European And US Vaccine Stocks Are Under Pressure – Here’s Why

Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.

The persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age).

No safety concerns were reported or identified during the two-year follow-up, and no Adverse Event of Special Interest were ongoing during participant enrollment in the trial.

IXCHIQ is the world’s first and only licensed chikungunya vaccine.

The vaccine is currently approved in the U.S., Europe, and Canada to prevent disease caused by the chikungunya virus in individuals 18 and older.

Valneva recently submitted label extension applications to the FDA, the European Medicines Agency, and Health Canada to potentially extend the use of its chikungunya vaccine IXCHIQ to adolescents aged 12 to 17 years.

Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, “We are extremely pleased about these three-year data which further highlight IXCHIQ’s differentiated product profile and ability to induce a robust, long-lasting antibody response in both younger and older adults with a single vaccination.”

In September, Valneva and Pfizer Inc. PFE released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.

One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination before each Lyme season.

Price Action: VALN stock is up 2.58% at $3.97 at last check Tuesday.

Read Next:

• Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Image via Shutterstock.